Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL
NCT06463691Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonrotoclax in mantle cell lymphoma (MCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Complete Response Rate at Cycle 12. Started Aug 2024; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06463691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463691.